# Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy

> **NCT00086541** · PHASE3 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 515 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks

## Key facts

- **NCT ID:** NCT00086541
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** —
- **Final completion:** 2007-01
- **Target enrollment:** 515 (ACTUAL)
- **Last updated:** 2019-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00086541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00086541, "Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00086541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*